Starpharma Holdings (ASX:SPL) Marketable Securities: A$0.00 Mil (As of Dec. 2025)


ASX:SPL Starpharma Holdings Ltd ASX:SPL
53 GF Score
Price A$0.71
GF Value A$0.44
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Starpharma Holdings Marketable Securities?

Starpharma Holdings ASX:SPL -0.70% 53 Marketable Securities is A$0.00 Mil as of Dec. 2025. GuruFocus rates ASX:SPL with a GF Score™ of 53/100 and a GF Value™ of A$0.44 (Significantly Overvalued). The stock has 3 warning signs investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Starpharma Holdings's Marketable Securities for the quarter that ended in Dec. 2025 was A$0.00 Mil.

Starpharma Holdings  (ASX:SPL) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Starpharma Holdings Marketable Securities Related Terms

Starpharma Holdings Marketable Securities Historical Data

* Premium members only.

The historical data trend for Starpharma Holdings's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Starpharma Holdings Marketable Securities Chart

Starpharma Holdings Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Marketable Securities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Starpharma Holdings Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
ASX:SPL
53GF Score
Starpharma Holdings Ltd ASX:SPL
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Starpharma Holdings Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of A$0.00 Mil mean?
Starpharma Holdings (ASX:SPL) has a Marketable Securities of A$0.00 Mil as of Dec. 2025. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Starpharma Holdings and its competitors.
Is Starpharma Holdings' Marketable Securities too high?
Starpharma Holdings' current Marketable Securities is A$0.00 Mil. Overall, Starpharma Holdings has a GF Score™ of 53/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Starpharma Holdings' Marketable Securities compare to VRTX and REGN?
Starpharma Holdings' Marketable Securities of A$0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Biotechnology company?
A good Marketable Securities depends on the Biotechnology industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Starpharma Holdings and its competitors. Starpharma Holdings's current Marketable Securities is A$0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Starpharma Holdings stock overvalued right now?
Based on GuruFocus' analysis, Starpharma Holdings (ASX:SPL) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.44, compared to a current price of A$0.71 — trading 61.4% above its estimated fair value. The current Marketable Securities is A$0.00 Mil. Starpharma Holdings' overall GF Score™ is 53/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For Starpharma Holdings (ASX:SPL), the current Marketable Securities is A$0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Starpharma Holdings (ASX:SPL) Overvalued in 2026?

Based on GuruFocus' analysis, Starpharma Holdings stock appears to be overvalued. The current stock price of A$0.71 is trading 61.4% above its estimated GF Value™ of A$0.44. GuruFocus considers Starpharma Holdings to be Significantly Overvalued.

Key valuation signals for ASX:SPL:

  • Marketable Securities: A$0.00 Mil
  • GF Value™: A$0.44 vs. price of A$0.71 (61.4% above fair value)
  • GF Score™: 53/100 with 3 warning signs

No single metric tells the full story. See the ASX:SPL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Starpharma Holdings Business Description

Address 4-6 Southampton Crescent, Abbotsford, Melbourne, VIC, AUS, 3067
Starpharma Holdings Ltd is an Australia-based company engaged in the research, development, and commercialization of dendrimer products for pharmaceutical, life science, and other applications. It focuses on the development of VivaGel for the management and prevention of bacterial vaginosis and as a condom coating, and VIRALEZE, an antiviral nasal spray.
53GF Score

Get the complete analysis for ASX:SPL

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.71
Price
A$0.44
GF Value